Kukjeon Co Ltd

Kukjeon Co Ltd maintains a debt-to-equity ratio of 0.8, indicating a relatively balanced capital structure, though it is leveraged with long-term debt of KRW 77,953,490,890. The company's liquidity position is assessed as medium, with a current ratio of 1.18 and negative free cash flow of KRW -5,362,423,490, suggesting that operating cash flow is insufficient to cover capital expenditures. The company's cash and equivalents of KRW 7,585,461,340 are significantly lower than its long-term debt, resulting in a net cash negative position.

Profitability metrics show a return on equity (ROE) of 1.22% and a return on assets (ROA) of 0.52%, both below the typical thresholds for pharmaceutical firms, which often aim for ROE above 10% and ROA above 5%. The company's operating margin is 4.08% (KRW 1,605,463,850 / KRW 39,310,131,900), which is weak compared to industry benchmarks.

Kukjeon's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's operations are entirely based in South Korea, and there is no indication of international revenue streams or segmental breakdowns in the latest financials.

The company's growth trajectory is uncertain, with no specific revenue growth targets or projections provided in the latest financial data. The capital expenditure of KRW -6,864,080,120 indicates a significant outflow, which may be related to facility upgrades or new product development, but the negative free cash flow suggests that these investments are not yet generating positive returns.

Risk factors include a medium liquidity risk due to the negative free cash flow and a net cash negative position. The company's dilution risk is assessed as low, with no recent share issuance or dilution events reported. However, the company's reliance on long-term debt and the absence of a clear path to positive free cash flow could pose challenges in the near term.

Recent events include the publication of the latest financial data, which provides a snapshot of the company's financial health as of the most recent reporting period. There are no disclosed regulatory actions, lawsuits, or major business developments in the latest filings or transcripts.

Free cash flow improved 48.4% year-over-year to -3.3 billion KRW, indicating a significant reduction in cash burn.

Cash conversion of 3.08 ranks best-in-class within the pharmaceutical cohort, suggesting superior operational efficiency relative to peers.

Long-term debt decreased to 45.9 billion KRW in FY0, down from 65.3 billion KRW in FY-1, reducing leverage.

Revenue maintained a 4-year CAGR of 11.3%, demonstrating historical top-line growth momentum despite recent volatility.

Dilution risk is assessed as low, providing some protection to existing shareholders against equity value erosion.

Credit risk is flagged as high, indicating significant potential for financial distress or default given current leverage levels.

Debt-to-equity ratio of 0.8 places the company in the bottom quartile of the pharmaceutical cohort, implying excessive leverage.

Return on equity of 1.2% is significantly below the cohort median of 2.9%, indicating poor capital generation capability.